Cargando…

Disease Activity and Progression of Disability in Multiple Sclerosis Patients Aged Over 50 With or Without Disease-Modifying Drug Treatment: A Retrospective Cohort Study

Background This study aimed to clarify the need for disease-modifying drug (DMD) treatment in elderly patients with multiple sclerosis (MS) aged 50 years or older. MS is an autoimmune, demyelinating disease of the central nervous system that predominantly affects young women. Various DMDs are effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kondo, Akihiro, Ikeguchi, Ryotaro, Kitagawa, Kazuo, Shimizu, Yuko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697689/ http://dx.doi.org/10.7759/cureus.49927

Ejemplares similares

Melanoma Cell Adhesion Molecule Expressing Helper T Cells in CNS Inflammatory Demyelinating Diseases
por: Ikeguchi, Ryotaro, et al.
Publicado: (2021)

The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses
por: Claflin, Suzi B., et al.
Publicado: (2019)

Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis
por: Hänninen, Katariina, et al.
Publicado: (2020)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis
por: Oyama, Munenori, et al.
Publicado: (2020)

Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies
por: Simone, Isabella Laura, et al.
Publicado: (2021)

Multimodal diagnostics in multiple sclerosis: predicting disability and conversion from relapsing-remitting to secondary progressive disease course – protocol for systematic review and meta-analysis
por: Statsenko, Yauhen, et al.
Publicado: (2023)

Multiple sclerosis and exercise—A disease-modifying intervention of mice or men?
por: Martin, Sarah-Jane, et al.
Publicado: (2023)

Consensus on early detection of disease progression in patients with multiple sclerosis
por: Meca-Lallana, José E., et al.
Publicado: (2022)

Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review
por: Capone, Fioravante, et al.
Publicado: (2022)

Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies
por: Simoens, Steven
Publicado: (2022)

Paraneoplastic AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder Associated With Teratoma: A Case Report and Literature Review
por: Ikeguchi, Ryotaro, et al.
Publicado: (2021)

Factors Influencing the Degree of Disability in Patients With Multiple Sclerosis
por: Xue, Huiru, et al.
Publicado: (2021)

Serotonergic drug repurposing in multiple sclerosis: A new possibility for disease-modifying therapy
por: Melnikov, Mikhail, et al.
Publicado: (2022)

Prevalence of Vestibular Disorders in Independent People Over 50 That Experience Dizziness
por: Figtree, William V. C., et al.
Publicado: (2021)

Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study)
por: Saji, Naoki, et al.
Publicado: (2018)

Silent Free Fall at Disease Onset: A Perspective on Therapeutics for Progressive Multiple Sclerosis
por: LoPresti, Patrizia
Publicado: (2018)

Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis
por: Blok, Katelijn M., et al.
Publicado: (2023)

Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies
por: Sgarlata, Eleonora, et al.
Publicado: (2022)

Four Cases of Suspected Levetiracetam-Induced Asymptomatic Rhabdomyolysis
por: Saito, Satoshi, et al.
Publicado: (2023)

The Contribution of Various MRI Parameters to Clinical and Cognitive Disability in Multiple Sclerosis
por: Tóth, Eszter, et al.
Publicado: (2019)

Deciphering Multiple Sclerosis Progression
por: Meca-Lallana, Virginia, et al.
Publicado: (2021)

Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies
por: Bridge, Francesca, et al.
Publicado: (2023)

The impact of disease modifying therapies on cognitive functions typically impaired in multiple sclerosis patients: a clinician’s review
por: Kania, Karolina, et al.
Publicado: (2023)

How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years
por: Epelbaum, Stéphane, et al.
Publicado: (2019)

Development and Internal Validation of a Disability Algorithm for Multiple Sclerosis in Administrative Data
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Clinical Profile and the Extent of Disability in Multiple Sclerosis Patients in Madinah, Saudi Arabia
por: Alsaedi, Esraa Q, et al.
Publicado: (2022)

How is neuromuscular fatigability affected by perceived fatigue and disability in people with multiple sclerosis?
por: Royer, Nicolas, et al.
Publicado: (2022)

Saccular functions differ for Meniere’s disease with and without coexisting headaches
por: Inui, Takaki, et al.
Publicado: (2023)

The impact of upper motor neuron involvement on clinical features, disease progression and prognosis in amyotrophic lateral sclerosis
por: Colombo, Eleonora, et al.
Publicado: (2023)

Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis
por: Vollmer, Brandi L., et al.
Publicado: (2022)

Smartphone Level Test Measures Disability in Several Neurological Domains for Patients With Multiple Sclerosis
por: Boukhvalova, Alexandra K., et al.
Publicado: (2019)

A Comprehensive Approach to Disentangle the Effect of Cerebellar Damage on Physical Disability in Multiple Sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2020)

Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure
por: Manouchehri, Navid, et al.
Publicado: (2022)

Cognitive impairment in Chinese adult patients with type III spinal muscular atrophy without disease-modifying treatment
por: Hu, Ying, et al.
Publicado: (2023)

Predictive value of brain atrophy, serum biomarkers and information processing speed for early disease progression in multiple sclerosis
por: Oset, Magdalena, et al.
Publicado: (2023)

Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study
por: Al-Sakran, Lina, et al.
Publicado: (2019)

Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis
por: Amoriello, Roberta, et al.
Publicado: (2022)

Additive Effect of Spinal Cord Volume, Diffuse and Focal Cord Pathology on Disability in Multiple Sclerosis
por: Andelova, Michaela, et al.
Publicado: (2019)

Retrospective cohort study of the relationship between systolic blood pressure variability and multiple sclerosis disability
por: Goldman, Myla D, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_haue2tko6ml3rejqud8sb850v3